The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era
The optimal approach to patients with chronic myeloid leukemia (CML) who relapse following allogeneic hematopoietic cell transplantation (HCT) in the tyrosine kinase inhibitor (TKI) era is unknown. Imatinib was introduced in 2001, followed by the introduction of second-generation TKIs such as dasatinib or nilotinib in subsequent years [1,2]. In later years, the spectrum of TKIs has further broadened, given the introduction of bosutinib and ponatinib [3,4]. Nevertheless, allogeneic HCT remains an important rescue strategy for some patients with CML at adverse risk.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Sarah Schmidt, Ying Liu, Zhen-Huan Hu, Kirsten M. Williams, Hillard M. Lazarus, Ravi Vij, Mohamed A. Kharfan-Dabaja, Guillermo Ort í, Peter H. Wiernik, Daniel Weisdorf, Rammurti T. Kamble, Roger Herzig, Baldeep Wirk, Jan Cerny, Ulrike Bacher, Naeem A. Ch Source Type: research
More News: Biology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Nilotinib | Tasigna | Transplants